Research Analysts Issue Forecasts for DNLI FY2026 Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) – Research analysts at HC Wainwright issued their FY2026 earnings estimates for Denali Therapeutics in a note issued to investors on Wednesday, November 4th. HC Wainwright analyst A. Ghosh forecasts that the company will post earnings of ($1.61) per share for the year. HC Wainwright has a “Strong-Buy” rating on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($1.94) per share. HC Wainwright also issued estimates for Denali Therapeutics’ Q4 2026 earnings at ($0.62) EPS, FY2027 earnings at ($2.38) EPS, FY2028 earnings at ($1.77) EPS, FY2029 earnings at ($1.51) EPS and FY2030 earnings at ($0.14) EPS.

Denali Therapeutics (NASDAQ:DNLI – Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The company reported $0.37 EPS for the quarter, beating the consensus estimate of ($0.27) by $0.64. The firm had revenue of $17.78 million for the quarter, compared to analysts’ expectations of $12.67 million. During the same period in the previous year, the company posted ($0.74) earnings per share.

Other analysts have also recently issued research reports about the company. Morgan Stanley raised their price objective on Denali Therapeutics from $40.00 to $42.00 and gave the stock an “overweight” rating in a research report on Wednesday. Wedbush upped their target price on Denali Therapeutics from $23.00 to $24.00 and gave the company an “outperform” rating in a research report on Wednesday. BTIG Research reiterated a “buy” rating and issued a $39.00 price target on shares of Denali Therapeutics in a research note on Wednesday. UBS Group raised their price target on Denali Therapeutics from $25.00 to $34.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on Denali Therapeutics from $31.00 to $35.00 and gave the stock a “buy” rating in a research note on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $36.15.

View Our Latest Report on DNLI

Denali Therapeutics Stock Up 1.8%

Shares of Denali Therapeutics stock opened at $20.07 on Friday. The company has a quick ratio of 8.32, a current ratio of 6.21 and a debt-to-equity ratio of 0.01. The company has a market cap of $3.22 billion, a P/E ratio of -11.60 and a beta of 1.08. The firm’s 50 day moving average price is $20.16 and its 200-day moving average price is $21.27. Denali Therapeutics has a 52-week low of $13.75 and a 52-week high of $27.30.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. BlackRock Inc. acquired a new stake in shares of Denali Therapeutics during the second quarter worth about $360,759,000. Dimensional Fund Advisors LP increased its holdings in Denali Therapeutics by 13.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,692,175 shares of the company’s stock worth $51,687,000 after buying an additional 317,872 shares during the period. Fisher Asset Management LLC increased its holdings in Denali Therapeutics by 1.9% in the 3rd quarter. Fisher Asset Management LLC now owns 2,460,545 shares of the company’s stock worth $50,859,000 after buying an additional 46,383 shares during the period. ADAR1 Capital Management LLC increased its holdings in Denali Therapeutics by 3,490.9% in the 1st quarter. ADAR1 Capital Management LLC now owns 1,871,455 shares of the company’s stock worth $35,932,000 after buying an additional 1,819,339 shares during the period. Finally, Aberdeen Group plc raised its position in Denali Therapeutics by 13.0% during the 3rd quarter. Aberdeen Group plc now owns 1,520,605 shares of the company’s stock worth $31,431,000 after buying an additional 175,124 shares during the last quarter. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Denali Therapeutics news, insider Alexander O. Schuth sold 2,768 shares of Denali Therapeutics stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $23.44, for a total transaction of $64,881.92. Following the completion of the sale, the insider owned 278,995 shares of the company’s stock, valued at approximately $6,539,642.80. The trade was a 0.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 9.70% of the company’s stock.

More Denali Therapeutics News

Here are the key news stories impacting Denali Therapeutics this week:

  • Positive Sentiment: Denali’s third-quarter results beat expectations: EPS was $0.37 versus the consensus estimate of a $0.27 loss, and revenue was $17.78 million versus a $12.67 million estimate. Denali Therapeutics earnings beat and valuation article
  • Positive Sentiment: Commercial momentum and potential catalysts may be lifting sentiment: a report cited nearly fivefold growth in Avlayah sales, broader reimbursement coverage, and multiple upcoming pipeline catalysts. Shares were reported up 7.8% after the earnings release. Zacks report on Denali post-earnings performance
  • Positive Sentiment: HC Wainwright initiated coverage with a “Strong Buy” rating, providing a new bullish analyst view. HC Wainwright stock recommendations
  • Neutral Sentiment: HC Wainwright’s forecasts show losses continuing in coming years, though its estimates narrow to a $0.14-per-share loss by 2030. The longer-term outlook is therefore still dependent on commercial growth and pipeline progress.
  • Neutral Sentiment: A separate report put Denali’s valuation back in focus after the earnings-driven move, suggesting investors may weigh the improved results against the stock’s valuation. Denali earnings and valuation article

About Denali Therapeutics

(Get Free Report)

Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing therapies for patients with neurodegenerative diseases. The company’s research programs target conditions including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and lysosomal storage disorders.

Denali uses its blood-brain barrier transport technology, known as the Transport Vehicle platform, to design medicines intended to deliver therapeutic proteins and other biologic treatments into the central nervous system.

See Also

Earnings History and Estimates for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.